NeuroPred-GMC: a dual-branch deep learning architecture for neuropeptide prediction based on gated dilated convolutional network and multi-scale convolutional network.
Neuropeptide research just got a major tech upgrade. Liang and Cao have introduced NeuroPred-GMC, a dual-branch deep learning model that predicts neuropeptides with impressive accuracy. This isn’t just about faster computation. It’s about opening up new possibilities for the whole field of peptide research.
J Comput Aided Mol Des
by Liang Y, Cao M
“NeuroPred-GMC: a dual-branch deep learning architecture for neuropeptide prediction based on gated dilated convolutional network and multi-scale convolutional network. Liang Y(1), Cao M(2). Author information: (1)School of Science, Xi'an Polytechnic University, Xi'an, 710048, People's Republic of China. yunyunliang88@163.com. (2)School of Science, Xi'an Polytechnic University, Xi'an, 710048, People's Republic of China. Neuropeptides are multifunctional signaling molecules in the nervous system. By modulating synaptic transmission and integrating physiological systems, they influence a broad range of functions from pain perception to emotional regulation. Predicting neuropeptides can rapidly expand the library of potential therapeutic targets, thereby providing novel candidate molecules for drug development in areas such as analgesics, anti-anxiety medications, and weight-loss drugs. Traditional experimental methods are extremely time-consuming, labor-intensive, these promising alternative computational methods have emerged. In this study, a dual-branch deep learning architecture for neuropeptide prediction known as NeuroPred-GMC are built up based on gated dilated convolutional network with ESM-2 feature representation and multi-scale convolutional network with Prot-T5 feature representation. Dilated convolution exponentially enlarges the receptive field via increased dilation rates, gating mechanism enables dynamic, selective feature enhancement and noise suppression, and multi-scale convolution captures multi-level contextual information. On the independence test set, the accuracy of 93.24%, Sn of 93.69%, Sp of 92.79%, Pre of 92.86%, MCC of 0.8649 and the auROC of 0.9667 are obtained. The experimental results through cross-validation and independent test demonstrate that the proposed model has good robustness and generalizability, and can serve as a supplemental candidate predictor. The source datasets and codes can be freely available at https://github.com/yunyunliang88/NeuroPred-GMC . © 2026. The Author(s), under exclusive licence to Springer Nature Switzerland AG. Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.”
Neuropeptides do a lot — they shape everything from pain response to emotional states. The old way to identify them relied on slow, expensive lab work. Now, with tools like NeuroPred-GMC, researchers can rapidly scan sequences and spot promising neuropeptide candidates in silico.
Key features behind NeuroPred-GMC’s performance:
Two parallel branches: one uses a gated dilated convolutional network with ESM-2 features, the other uses a multi-scale convolutional network with Prot-T5 features
Dilated convolutions massively expand the context window, so the model can “see” more of the sequence at once
Gating helps filter out noise, focusing on the most relevant signals
Multi-scale convolutions capture patterns at different levels of detail
On independent test data, NeuroPred-GMC hit 93.24% accuracy and an auROC of 0.9667. That’s strong even by modern deep learning standards. The model’s robustness and generalizability mean it isn’t just a one-off — it’s built to handle new and diverse data.
For the peptide research community, this is a big step. Faster, more accurate neuropeptide prediction could accelerate the discovery of new bioactive compounds. That means more potential research targets for everything from pain management to mood regulation.
You can check out the source code and datasets on GitHub if you want to dig into the details. For more on the state of peptide research and related computational tools, start with the peptide research index.
NeuroPred-GMC sets a new bar for what’s possible in neuropeptide prediction — and it’s available for the whole research community to build on.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.